1. Circ Cardiovasc Interv
Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents
by Anna Franzone, Thomas Pilgrim, Dik Heg, Marco Roffi, David Tüller, André Vuilliomenet, Olivier Muller, Stéphane Cook, Daniel Weilenmann, Christoph Kaiser, Peiman Jamshidi, Lorenz Räber, Stefan Stortecky, Peter Wenaweser, Peter Jüni, and Stephan Windecker
Circ Cardiovasc Interv
Volume 8(6):e002319
June 4, 2015
Copyright © American Heart Association, Inc. All rights reserved.

2. Patient flow according to the CONSORT statement.
Patient flow according to the CONSORT statement. BMS indicates bare-metal stents; BP-SES, biodegradable polymer sirolimus-eluting stents; CABG, coronary artery bypass grafting; DP-EES, durable polymer everolimus-eluting stents; PCI, percutaneous coronary intervention; and STEMI, ST-segment–elevation myocardial infarction.
Anna Franzone et al. Circ Cardiovasc Interv. 2015;8:e002319
Copyright © American Heart Association, Inc. All rights reserved.

3. Time to event curves for the composite end point target lesion failure and individual components of the primary end point ≤12 months of follow-up in diabetic and nondiabetic patients.
Time to event curves for the composite end point target lesion failure and individual components of the primary end point ≤12 months of follow-up in diabetic and nondiabetic patients. A, Target lesion failure; B, cardiac death; C, target-vessel (TV) myocardial infarction; D, clinically indicated target lesion revascularization (TLR). Blue lines indicate biodegradable polymer sirolimus-eluting stent and red lines indicate durable polymer everolimus-eluting stent. Diabetic patients, solid lines; nondiabetic patients, dashed lines. CI indicates confidence interval; DM, diabetes mellitus; and HR, hazard ratio.
Anna Franzone et al. Circ Cardiovasc Interv. 2015;8:e002319
Copyright © American Heart Association, Inc. All rights reserved.